Skip to Content

'
Lauren Averett Byers, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2009 University of Texas Graduate School of Biomedical Sciences, Houston, TX, MS, Cancer Biology (specialization in Patient-Based Research)
2003 Baylor College of Medicine, Houston, TX, MD, Medicine
1998 Princeton University, Princeton, NJ, BA, Molecular Biology

Postgraduate Training

7/2009-7/2010 Advanced Scholars Program, Medical Oncology Research, The University of Texas MD Anderson Cancer Center, Houston, TX, Waun Ki Hong, MD, Program Director
7/2006-6/2009 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert A. Wolff, MD, Program Director
7/2003-6/2006 Clinical Residency, Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, Charles Wiener, MD, Program Director

Board Certifications

11/2010 Medical Oncology, American Board of Internal Medicine
8/2006 Internal Medicine, American Board of Internal Medicine

Honors and Awards

2014 President's Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center
2013-present 2013 NCI Cancer Clinical Investigator Team Leadership Award, National Cancer Institute
2013-present Khalifa Scholar and Fellows Award, The Sheikh Khalifa Bin Zayed Al Nahyan Institute for the Personalized Cancer Therapy's (IPCT's) Center for Professional Education and Training
2013-present Sidney Kimmel Scholars Award, The Sidney Kimmel Foundation for Cancer Research
2013 Women Leading the Way, Women Faculty Programs, MDACC
2010-present Physician Scientist Award, The University of Texas MD Anderson Cancer Center
2010 Scholar-in-Training Award, AACR Annual Meeting
2009 Achievement in Basic Science Research Award, Division of Cancer Medicine/Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center
2009 Merit Award, ASCO Annual Meeting, American Society of Clinical Oncology
2008 Clinical Fellow Award, A. Lavoy Moore Endowment Fund, The University of Texas MD Anderson Cancer Center
2008 Merit Award, ASCO Annual Meeting, American Society of Clinical Oncology
2008 Merit Award, ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, American Society for Clinical Oncology
2008 Merit Award, IASCL 8th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting, International Association for the Study of Lung Cancer
2008 Trainee Excellence Award, The University of Texas MD Anderson Cancer Center
2007-2009 Clinical Research Loan Repayment Program Award, NIH
2007 Merit Award, AACR-NCI-EORTC Molecular Targets Meeting, American Association for Cancer Research
2002 First Prize Basic Science Research, J. Alexander Research Symposium, Baylor College of Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Chen L, Gibbons DL, Goswami S, Ahn Y-H, Byers LA, Cortez A, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Ungewiss C, Peng D, Robertson G, Welsh J, Peng D, Wang S, Ullrich SE, Chen L, Wistuba II, Heymach JV, Kurie JM, Qin FXF. Tumor metastasis is regulated via microRNA-200/ZEB1 axis control of PD-L1 expression on tumor cells and intra-tumoral immunosuppression. Nature Communications. In Press.
2. Gibbons DL, Byers LA. A Her-1 -2 punch: Dual EGFR targeting deals resistance a deadly blow. Cancer Discov 4(9):991-4, 9/2014. PMID: 25185188.
3. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM. Multi-platform analysis of 12 cancer types reveals molecular classification within and across tissues-of-origin. Cell 158(4):929-44, 8/2014. e-Pub 8/2014. PMCID: PMC4152462.
4. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-50, 7/2014. e-Pub 7/2014. PMID: 25079552.
5. Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer 120(6):790-8, 3/2014. e-Pub 12/2013. PMCID: PMC3947683.
6. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 5:3887, 2014. e-Pub 5/2014. PMCID: PMC4109726.
7. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 19(22):6322-8, 11/2013. e-Pub 9/2013. PMCID: PMC3882158.
8. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer. Cancer Discov 3(8):870-9, 8/2013. e-Pub 5/2013. PMCID: PMC3753578.
9. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-290, 1/2013. e-Pub 10/2012. PMCID: PMC3567921.
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519-25, 9/2012. e-Pub 9/2012. PMCID: PMC3466113.
11. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2(9):798-811, 9/2012. e-Pub 9/2012. PMCID: PMC3567922.
12. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. J Natl Cancer Inst 104(3):228-39, 2/2012. e-Pub 1/2012. PMCID: PMC3274509.
13. Nanjundan M*, Byers LA* (co-first authors), Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 5(12):1894-904, 12/2010. PMID: 21124077.
14. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.
15. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-61, 11/2009. e-Pub 10/2009. PMCID: PMC2935176.
16. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2):185-97, 2/2003. PMID: 12620412.
17. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937-47, 6/2002. PMID: 12075054.

Grant & Contract Support

Title: Investigation of Chk1 targeting and potential predictive biomarkers in small cell lung cancer (SCLC)
Funding Source: R. Lee Clark Fellow Award
Role: Principal Investigator
Duration: 4/1/2014 - 3/31/2016
 
Title: Khalifa Scholars and Fellows Award
Funding Source: The Sheikh Khalifa Bin Zayed Al Nahyan Institute for the Personalized Cancer Therapy's (IPCT's) Center for Professional Education and Training
Role: Principal Investigator
Duration: 1/1/2014 - 12/31/2014
 
Title: Proteomic Profiling of Salivary Tumors to Identify Novel Therapeutic Targets
Funding Source: Salivary Gland U01 Career Development Project Award
Role: Principal Investigator
Duration: 12/1/2013 - 11/30/2014
 
Title: 2013 NCI Cancer Clinical Investigator Team Leadership Award
Funding Source: National Cancer Institute
Role: Principal Investigator
Duration: 9/1/2013 - 8/31/2015
 
Title: Co-targeting of PARP1 and the PI3K/mTOR pathway in SCLC
Funding Source: The Sidney Kimmel Foundation for Cancer Research
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2015
 
Title: Co-targeting of PARP1 and Resistance Pathways in SCLC
Funding Source: National Lung Cancer Partnership
Role: Principal Investigator
Duration: 1/1/2013 - 12/31/2015
 
Title: PARP1 as a novel therapeutic target in small cell lung cancer (SCLC)
Funding Source: LUNGevity Foundation
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2015
 
Title: Markers and therapeutic strategies for overcoming chemoradiotherapy resistance
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Heymach
Duration: 10/1/2011 - 9/30/2016
 
Title: Physician Scientist Award
Funding Source: UT MD Anderson Cancer Center
Role: Principal Investigator
Duration: 6/1/2011 - 5/31/2015
 
Title: A Phase I, First in Human, Single-Arm, Open-label study of once a day, orally administered BMN673 (PARP inhibitor) in patients with advanced or recurrent solid tumors
Funding Source: BioMarin
Role: Co-Principal Investigator
Duration: 1/1/2011 - 11/20/2017
 
Title: Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: John Weinstein
Duration: 3/1/2010 - 7/31/2015

Last updated: 9/30/2014